Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs

Author： Schönthal Axel H   Chen Thomas C   Hofman Florence M   Louie Stan G   Petasis Nicos A  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.17, Iss.2, 2008-02, pp. : 197-208

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anticancer Metallotherapeutics in Preclinical Development

By  

Current Medicinal Chemistry, Vol. 18, Iss. 31, 2011-11 ,pp. : 4738-4752

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical pharmacology of celecoxib, a COX-2 selective inhibitor

By Antoniou Katerina   Malamas Michael   Drosos Alexandros A  

Expert Opinion on Pharmacotherapy, Vol. 8, Iss. 11, 2007-08 ,pp. : 1719-1732

Informa Healthcare

Access to resources Recommend Favorite

Disulfiram, and Disulfiram Derivatives as Novel Potential Anticancer Drugs Targeting the Ubiquitin Proteasome System in Both Preclinical and Clinical Studies

By  

Current Cancer Drug Targets, Vol. 11, Iss. 3, 2011-03 ,pp. : 338-346

Bentham Science Publishers

Access to resources Recommend Favorite

An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs

By  

Current Topics in Medicinal Chemistry, Vol. 16, Iss. 19, 2016-08 ,pp. : 2156-2168

Bentham Science Publishers

Access to resources Recommend Favorite

Lesson Learned from Nature for the Development of Novel Anti-Cancer Agents: Implication of Isoflavone, Curcumin, and their Synthetic Analogs

By  

Current Pharmaceutical Design, Vol. 16, Iss. 16, 2010-06 ,pp. : 1801-1812

Bentham Science Publishers

Access to resources Recommend Favorite